Skip to main content
Premium Trial:

Request an Annual Quote

Salk Institute, Indivumed Enter Research Partnership

NEW YORK (GenomeWeb) – The Salk Institute and cancer research firm Indivumed said today that they have entered a multi-year strategic alliance focused on the collection and analysis of samples and clinical data for translational research applications.

Under the agreement, Indivumed will provide dedicated resources to assist Salk Cancer Center researchers in planning for and acquiring annotated cancer biospecimens to support specific basic and translational research projects.

Salk and Indivumed also plan to develop a portfolio of collaborative research projects, to which both organizations will contribute resources, with the goal of developing a global cancer database of molecular and phenotypic data sets.

Financial terms of the deal were not disclosed

Indivumed Founder and CEO Hartmut Juhl said in a statement that his company believes that opening its molecular and phenotypic data sets to the expertise of the Salk institute will create a powerful new research engine.

Reuben Shaw, director of the Salk Cancer Center added that the institute believes that Indivumed's "controlled and rapid tissue processing" offers an invaluable research resource which could have a "transformational impact on our research and ultimately our understanding of cancer."